Drug Profile
Research programme: CNS disorders RNA interference-based therapeutics - Alnylam Pharmaceuticals
Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Sirna Therapeutics
- Developer Alnylam Pharmaceuticals; Sirna Therapeutics
- Class Antidementias; Neuroprotectants; RNA; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
- No development reported Cerebral amyloid angiopathy; Neurodegenerative disorders
- Discontinued Spinocerebellar degeneration
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Cerebral-amyloid-angiopathy in USA (Parenteral)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (Intrathecal, Injection)
- 24 Dec 2021 Alnylam Pharmaceuticals submits CTA application to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for the treatment of Alzheimer’s disease and Cerebral amyloid angiopathy